This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
HLA class I-restricted T cell epitopes isolated and identified from myeloid leukemia cells
Scientific Reports Open Access 01 October 2019
-
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia
Experimental Hematology & Oncology Open Access 11 January 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sugiyama H . Wilms tumor gene WT1 as a tumor marker for leukemic blast cells and its role in leukemogenesis. Methods Mol Med 2002; 68: 223–237.
Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885–13890.
Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009; 113: 6541–6548.
Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071–3079.
Murao A, Oka Y, Tsuboi A, Elisseeva OA, Tanaka-Harada Y, Fujiki F et al. High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organ. Cancer Sci 2010; 101: 848–854.
Jacobsohn DA, Tse WT, Chaleff S, Rademaker A, Duerst R, Olszewski M et al. High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. Br J Haematol 2009; 146: 669–674.
Ohta H, Hashii Y, Yoneda A, Takizawa S, Kusuki S, Tokimasa S et al. WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report. Pediatr Hematol Oncol 2009; 26: 74–83.
Kawakami M, Oka Y, Tsuboi A, Harada Y, Elisseeva OA, Furukawa Y et al. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. Int J Hematol 2007; 85: 426–429.
Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323–5337.
Hashii Y, Sato E, Ohta H, Oka Y, Sugiyama H, Ozono K . WT1 peptide immunotherapy for cancer in children and young adults. Pediatr Blood Cancer 2010; 55: 352–355.
Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698–1704.
Tamaki H, Mishima M, Kawakami M, Tsuboi A, Kim EH, Hosen N et al. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int J Hematol 2003; 78: 349–356.
Tobal K, Newton J, Macheta M, Chang J, Morgenstern G, Evans PA et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000; 95: 815–819.
Klebanoff CA, Gattinoni L, Restifo NP . CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006; 211: 214–224.
Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236–242.
Acknowledgements
We thank Ms Tokuko Okuda for analyzing WT1-specific CTLs.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Hashii, Y., Sato-Miyashita, E., Matsumura, R. et al. WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission. Leukemia 26, 530–532 (2012). https://doi.org/10.1038/leu.2011.226
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.226
This article is cited by
-
Identification of mouse helper epitopes for WT1-specific CD4+ T cells
Cancer Immunology, Immunotherapy (2021)
-
HLA class I-restricted T cell epitopes isolated and identified from myeloid leukemia cells
Scientific Reports (2019)
-
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia
Experimental Hematology & Oncology (2018)
-
Understanding CD8+ T‐cell responses toward the native and alternate HLA‐A∗02:01‐restricted WT1 epitope
Clinical & Translational Immunology (2017)
-
Two distinct effector memory cell populations of WT1 (Wilms’ tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients
Cancer Immunology, Immunotherapy (2015)